Condie 1985.

Methods	Study design: parallel RCT; stratified according to age, histocompatibility, transfusion history Study duration: not reported Study follow‐up: 3 years
Participants	Country: USA Setting: multicentre (4) Inclusion criteria: adults 1st DD kidney transplant recipients Number: treatment group (81); control group (79) Mean age: treatment group (37.8); control group (35.5) Sex (males): treatment group (75.3%); control group (74.7%) Exclusion criteria: contraindication of positive skin test; presence of circulating antibodies to horse products
Interventions	Treatment group Minnesota equine ALG: 30 mg/kg/d IV for 14 days PRED and AZA: dosing regimen not reported Control group Human albumin 30 mg/kg/d IV for 14 days PRED and AZA: dosing regimen not reported
Outcomes	Death Graft loss Acute rejection Infection Malignancy Side effects
Notes	Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double blind
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not blinded, may affect some but not all outcomes
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patient outcome data reported
Selective reporting (reporting bias)	High risk	Expected outcomes reported, however acute rejection rates and SCr not fully reported (short‐term only)
Other bias	Unclear risk	Funding not reported